BLyS/BAFF: a potential target in the treatment of active systemic lupus erythematosus.
Division of Allergy and Clinical Immunology, Bnai Zion Medical Center, Technion Faculty of Medicine, Haifa, Israel.
Elias
E
Toubi
Yehuda
Y
Shoenfeld
D053265:B-Cell Activation Factor Receptor; D006801:Humans; D008180:Lupus Erythematosus, Systemic / Q000188:drug therapy* / Q000503:physiopathology; D008565:Membrane Proteins / Q000097:blood / Q000276:immunology / Q000502:physiology*; D018124:Receptors, Tumor Necrosis Factor / Q000037:antagonists & inhibitors / Q000097:blood / Q000276:immunology / Q000502:physiology*; D015398:Signal Transduction / Q000502:physiology; D013582:Synovial Fluid / Q000276:immunology
D053265:B-Cell Activation Factor Receptor; C120197:BLyS receptor; D008565:Membrane Proteins; D018124:Receptors, Tumor Necrosis Factor; C435926:TNFRSF13C protein, human